Veracyte (VCYT) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price targets for Veracyte's stock. Their VCYT share price targets range from $21.00 to $34.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 46.4% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $27.51 at the beginning of the year. Since then, VCYT shares have decreased by 28.0% and is now trading at $19.81.
View the best growth stocks for 2024 here.

Veracyte saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average trading volume of 633,600 shares, the short-interest ratio is currently 5.7 days.
View Veracyte's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our VCYT earnings forecast.

Veracyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The biotechnology company had revenue of $98.20 million for the quarter, compared to the consensus estimate of $95.49 million. Veracyte had a negative net margin of 20.61% and a negative trailing twelve-month return on equity of 2.02%.

ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Invesco Biotechnology & Genome ETF (PBE), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Veracyte issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.46%), AMI Asset Management Corp (0.27%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.